Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-induction hypotension with remimazolam vs etomidate in elderly general anesthesia
ChiCTR2200055558Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam and etomidate in perioperative hypotension and Anaesthesia-related hemodynamic instability (ARHI) (3 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Incidence of post-induction hypotension. Started Jan 2022; status: recruiting.
02
Drugs
remimazolametomidate
03
Conditions
perioperative hypotensionAnaesthesia-related hemodynamic instability (ARHI)
Beyond the preview
Go deeper on ChiCTR2200055558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055558.